Related Experiment Video
Updated: Aug 16, 2025
Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model
Published on: March 20, 2020
Advances in Single-Cell Sequencing Technology and Its Applications in Triple-Negative Breast Cancer
Meng Li1, Tingting Yan1, Miaozhou Wang1
1Graduate School of Qinghai University, Qinghai University, Xining, Qinghai Province, People's Republic of China.
Abstract:
Triple-negative breast cancer (TNBC) is the most aggressive subtype of breast cancer and is mainly treated with chemotherapy-based combination therapy. In recent years, with the increasing development of global precision medicine, single-cell sequencing (SCS) has become one of the most promising technologies in the field of biotechnology. Moreover, the related application of this technology in TNBC has been applied and developed. By using SCS to study the heterogeneity of TNBC tumor cells, metastasis, drug resistance mechanisms, mutations, and cloning; it can further guide clinical chemotherapy, targeted therapy, and immunotherapy. To further reflect the importance of SCS in TNBC, this paper elaborated on and summarized the research and application progress of SCS in TNBC.
Insights
Single-cell sequencing (SCS) offers a powerful approach to understanding triple-negative breast cancer (TNBC) by analyzing tumor cell heterogeneity and guiding personalized treatments. This technology aids in developing targeted therapies and immunotherapies for this aggressive cancer subtype.
Area of Science:
- Biotechnology
- Oncology
- Genomics
Background:
- Triple-negative breast cancer (TNBC) is an aggressive breast cancer subtype.
- Current treatments primarily rely on chemotherapy-based combination therapy.
Purpose of the Study:
- To summarize the research and application progress of single-cell sequencing (SCS) in TNBC.
- To highlight the importance of SCS in advancing TNBC understanding and treatment.
Main Methods:
- Utilizing single-cell sequencing (SCS) technology.
- Analyzing TNBC tumor cell heterogeneity, metastasis, and drug resistance.
Main Results:
- SCS enables detailed study of TNBC tumor cell characteristics.
- It provides insights into mutations and clonal evolution within TNBC.
- SCS can guide clinical chemotherapy, targeted therapy, and immunotherapy strategies.
Conclusions:
- Single-cell sequencing is a crucial tool for understanding TNBC.
- SCS applications are advancing precision medicine for TNBC patients.
- Further research using SCS will improve treatment outcomes for TNBC.
